

Radiometals and radiohalogens: A potential new combination for cancer treatment

November 29 2021





Figure1: The word "theranostics," a portmanteau of the words "therapeutics" and "diagnostics." Theranostics with radioisotopes is called "radiotheranostics," which means the combination of imaging in nuclear medicine with radionuclide therapy. Probes for radiotheranostics could be produced by introducing radionuclides with similar chemical characteristics into the same precursors. Here, K. Ogawa et al. hypothesized that probes for radiotheranostics combined

with multiradionuclides, such as ^{68}Ga and ^{211}At , have useful clinical applications. New radiolabeled RGD peptide probes were synthesized via a molecular design approach, with two labeling sites for metal and halogen. These probes in radiotheranostics with multiradionuclides, such as a radiometal and a radiohalogen could contribute to a personalized medicine regimen. Credit: Kanazawa University

An approach called radiotheranostics involves a combination of a different kind for the treatment of cancer—namely, the combination of therapeutic and diagnostic techniques using radionuclides, chemical elements with unstable nuclei that emit radiation. Now, researchers in Japan have investigated a new strategy in radiotheranostics that involves another combination: metals and halogens.

In a study published in *Molecular Pharmaceutics*, researchers from Kanazawa University have demonstrated the feasibility of the dual application of diagnostic and therapeutic probes containing the radiometal gallium-68 (^{68}Ga) and the radiohalogen astatine-211 (^{211}At) for potential cancer [treatment](#).

In radiotheranostics, imaging techniques like positron emission topography (PET), which involves the use of radionuclide-labeled probes, are used to locate [tumor cells](#) in the body, and a radiolabeled drug is targeted to these tumor cell sites for treatment. Typically, the combination of imaging and therapeutic radionuclides is restricted to the use of elements with similar characteristics—for example, a therapeutic probe containing the radionuclide ^{211}At may be combined with a diagnostic probe containing iodine, because both elements are halogens. However, the combination of more diverse elements for radiotheranostic treatment would increase the versatility of this approach and allow for more personalized cancer treatment.



Representative single photon emission computed tomography (SPECT)/CT images. (a) axial SPECT/CT fusion image and (b) coronal MIP SPECT/CT fusion image of a U-87 MG tumor-bearing mouse at 4 h postinjection of ^{67}Ga -labeled RGD peptide. ^{67}Ga was used as an alternative radionuclide to ^{68}Ga . Arrows indicate the site where U-87 MG cells were inoculated. Credit: Kanazawa University

"We wanted to evaluate the use of radiotheranostic probes with different characteristics," says lead author Kazuma Ogawa. "Specifically, we investigated the use of a probe containing the metal ^{68}Ga , which is used in PET imaging to identify tumors, and a probe containing the halogen

^{211}At , which is used in targeted alpha therapy to treat tumors."

The researchers designed and synthesized three radionuclide-labeled probes each with two radiolabeling sites for the radiometal and radiohalogen. U-87 MG glioblastoma cells were used to evaluate the binding characteristics and stability of the probes, while tumor-bearing mice were used to evaluate the biodistribution, or where the probes traveled and accumulated within the body.

"We were pleased to see that the Ga-based probe and the At-based probe showed similar biodistribution and high accumulation in the mouse tumors," says senior author Seigo Kinuya.

The results indicate the potential for the use of multiradionuclide probes in radiotheranostic treatment. A greater diversity of [probe](#) combinations, such as the combination of a radiometal and radiohalogen evaluated here, may facilitate more personalized cancer treatments in the future.

More information: Kazuma Ogawa et al, ^{68}Ga - and ^{211}At -Labeled RGD Peptides for Radiotheranostics with Multiradionuclides, *Molecular Pharmaceutics* (2021). [DOI: 10.1021/acs.molpharmaceut.1c00460](https://doi.org/10.1021/acs.molpharmaceut.1c00460)

Provided by Kanazawa University

Citation: Radiometals and radiohalogens: A potential new combination for cancer treatment (2021, November 29) retrieved 11 August 2024 from <https://medicalxpress.com/news/2021-11-radiometals-radiohalogens-potential-combination-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.